PortalPublikationenEffective inhibition of metastases and primary tumor growth ...

Effective inhibition of metastases and primary tumor growth with CTCE-9908 in esophageal cancer

Standard

Effective inhibition of metastases and primary tumor growth with CTCE-9908 in esophageal cancer. / Drenckhan, Astrid; Kurschat, Nina; Dohrmann, Thorsten; Raabe, Nina; Koenig, Alexandra M; Reichelt, Uta; Kaifi, Jussuf T; Izbicki, Jakob R; Gros, Stephanie J.

in: J SURG RES, Jahrgang 182, Nr. 2, 15.06.2013, S. 250-6.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Drenckhan, A, Kurschat, N, Dohrmann, T, Raabe, N, Koenig, AM, Reichelt, U, Kaifi, JT, Izbicki, JR & Gros, SJ 2013, 'Effective inhibition of metastases and primary tumor growth with CTCE-9908 in esophageal cancer', J SURG RES, Jg. 182, Nr. 2, S. 250-6. https://doi.org/10.1016/j.jss.2012.09.035

APA

Drenckhan, A., Kurschat, N., Dohrmann, T., Raabe, N., Koenig, A. M., Reichelt, U., Kaifi, J. T., Izbicki, J. R., & Gros, S. J. (2013). Effective inhibition of metastases and primary tumor growth with CTCE-9908 in esophageal cancer. J SURG RES, 182(2), 250-6. https://doi.org/10.1016/j.jss.2012.09.035

Vancouver

Drenckhan A, Kurschat N, Dohrmann T, Raabe N, Koenig AM, Reichelt U et al. Effective inhibition of metastases and primary tumor growth with CTCE-9908 in esophageal cancer. J SURG RES. 2013 Jun 15;182(2):250-6. https://doi.org/10.1016/j.jss.2012.09.035

Bibtex

@article{742ae228ec6d4de28dd8d1bbbf4243f3,
title = "Effective inhibition of metastases and primary tumor growth with CTCE-9908 in esophageal cancer",
abstract = "BACKGROUND: In spite of multimodular treatment, the therapeutic options for esophageal carcinoma are limited, and metastases remain the leading cause of tumor-related mortality. Expression of the chemokine receptor CXCR4 significantly correlates with poor survival rates in patients with esophageal carcinoma and is associated with lymph node and bone marrow metastases. The aim of this study was to evaluate the effect of the CXCR4 antagonist CTCE-9908 on metastatic homing and primary tumor growth in vitro and in vivo in an orthotopic xenograft model of esophageal cancer.MATERIALS AND METHODS: OE19 cells were examined for stromal cell-derived factor 1 alpha-mediated migration under CTCE-9908 treatment. The CTCE-9908 treatment was further evaluated in an in vitro proliferation assay and orthotopic esophageal model, accompanied by magnetic resonance imaging. Tumor and metastases were immunohistochemically examined for CXCR4 expression.RESULTS: CTCE-9908 has an inhibitory effect on stromal cell-derived factor 1 alpha-mediated migration and proliferation of OE19 cells. Treatment with CTCE-9908 in the orthotopic esophageal model leads to a reduction of metastatic spread and primary tumor growth. This was confirmed by magnetic resonsance imaging. Treatment with CTCE-9908 results in altered CXCR4 expression pattern exhibiting a high degree of variability.CONCLUSION: CTCE-9908 effectively inhibits OE19 cell migration and proliferation in vitro, reduces metastases to lung, liver, and lymph nodes in vivo, and moreover leads to tumor growth reduction in an orthotopic model of esophageal carcinoma.",
keywords = "Animals, Antineoplastic Agents, Cell Line, Tumor, Cell Movement, Cell Proliferation, Esophageal Neoplasms, Humans, Liver Neoplasms, Lung Neoplasms, Magnetic Resonance Imaging, Mice, Peptides, Receptors, CXCR4",
author = "Astrid Drenckhan and Nina Kurschat and Thorsten Dohrmann and Nina Raabe and Koenig, {Alexandra M} and Uta Reichelt and Kaifi, {Jussuf T} and Izbicki, {Jakob R} and Gros, {Stephanie J}",
note = "Copyright {\textcopyright} 2013 Elsevier Inc. All rights reserved.",
year = "2013",
month = jun,
day = "15",
doi = "10.1016/j.jss.2012.09.035",
language = "English",
volume = "182",
pages = "250--6",
journal = "J SURG RES",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - Effective inhibition of metastases and primary tumor growth with CTCE-9908 in esophageal cancer

AU - Drenckhan, Astrid

AU - Kurschat, Nina

AU - Dohrmann, Thorsten

AU - Raabe, Nina

AU - Koenig, Alexandra M

AU - Reichelt, Uta

AU - Kaifi, Jussuf T

AU - Izbicki, Jakob R

AU - Gros, Stephanie J

N1 - Copyright © 2013 Elsevier Inc. All rights reserved.

PY - 2013/6/15

Y1 - 2013/6/15

N2 - BACKGROUND: In spite of multimodular treatment, the therapeutic options for esophageal carcinoma are limited, and metastases remain the leading cause of tumor-related mortality. Expression of the chemokine receptor CXCR4 significantly correlates with poor survival rates in patients with esophageal carcinoma and is associated with lymph node and bone marrow metastases. The aim of this study was to evaluate the effect of the CXCR4 antagonist CTCE-9908 on metastatic homing and primary tumor growth in vitro and in vivo in an orthotopic xenograft model of esophageal cancer.MATERIALS AND METHODS: OE19 cells were examined for stromal cell-derived factor 1 alpha-mediated migration under CTCE-9908 treatment. The CTCE-9908 treatment was further evaluated in an in vitro proliferation assay and orthotopic esophageal model, accompanied by magnetic resonance imaging. Tumor and metastases were immunohistochemically examined for CXCR4 expression.RESULTS: CTCE-9908 has an inhibitory effect on stromal cell-derived factor 1 alpha-mediated migration and proliferation of OE19 cells. Treatment with CTCE-9908 in the orthotopic esophageal model leads to a reduction of metastatic spread and primary tumor growth. This was confirmed by magnetic resonsance imaging. Treatment with CTCE-9908 results in altered CXCR4 expression pattern exhibiting a high degree of variability.CONCLUSION: CTCE-9908 effectively inhibits OE19 cell migration and proliferation in vitro, reduces metastases to lung, liver, and lymph nodes in vivo, and moreover leads to tumor growth reduction in an orthotopic model of esophageal carcinoma.

AB - BACKGROUND: In spite of multimodular treatment, the therapeutic options for esophageal carcinoma are limited, and metastases remain the leading cause of tumor-related mortality. Expression of the chemokine receptor CXCR4 significantly correlates with poor survival rates in patients with esophageal carcinoma and is associated with lymph node and bone marrow metastases. The aim of this study was to evaluate the effect of the CXCR4 antagonist CTCE-9908 on metastatic homing and primary tumor growth in vitro and in vivo in an orthotopic xenograft model of esophageal cancer.MATERIALS AND METHODS: OE19 cells were examined for stromal cell-derived factor 1 alpha-mediated migration under CTCE-9908 treatment. The CTCE-9908 treatment was further evaluated in an in vitro proliferation assay and orthotopic esophageal model, accompanied by magnetic resonance imaging. Tumor and metastases were immunohistochemically examined for CXCR4 expression.RESULTS: CTCE-9908 has an inhibitory effect on stromal cell-derived factor 1 alpha-mediated migration and proliferation of OE19 cells. Treatment with CTCE-9908 in the orthotopic esophageal model leads to a reduction of metastatic spread and primary tumor growth. This was confirmed by magnetic resonsance imaging. Treatment with CTCE-9908 results in altered CXCR4 expression pattern exhibiting a high degree of variability.CONCLUSION: CTCE-9908 effectively inhibits OE19 cell migration and proliferation in vitro, reduces metastases to lung, liver, and lymph nodes in vivo, and moreover leads to tumor growth reduction in an orthotopic model of esophageal carcinoma.

KW - Animals

KW - Antineoplastic Agents

KW - Cell Line, Tumor

KW - Cell Movement

KW - Cell Proliferation

KW - Esophageal Neoplasms

KW - Humans

KW - Liver Neoplasms

KW - Lung Neoplasms

KW - Magnetic Resonance Imaging

KW - Mice

KW - Peptides

KW - Receptors, CXCR4

U2 - 10.1016/j.jss.2012.09.035

DO - 10.1016/j.jss.2012.09.035

M3 - SCORING: Journal article

C2 - 23117118

VL - 182

SP - 250

EP - 256

JO - J SURG RES

JF - J SURG RES

SN - 0022-4804

IS - 2

ER -